Breaking News

Vertiflex Completes $40 Million Financing Round

By Business Wire | March 8, 2017

PMA approved Superion is demonstrating early commercial success.

Vertiflex Inc., a developer of advanced, minimally invasive interventions for spinal stenosis, today announced completion of a $40M financing round. New investors, Endeavour Vision and H.I.G. BioHealth Partners led the financing alongside existing investors, New Enterprise Associates; Thomas, McNerney & Partners; and Alta Partners. Proceeds from the financing will primarily be used to fund U.S. commercial expansion of the company’s Superion Indirect Decompression System, a minimally invasive spinal implant designed to treat moderate lumbar spinal stenosis, a painful and often debilitating condition that affects an estimated 500,000 new patients every year in the United States.
“Vertiflex has seen tremendous early success in the commercialization of the Superion System,” said Earl Fender, president and CEO of Vertiflex. “With favorable long-term clinical outcomes, a new Category I AMA CPT code and broad reimbursement in place, adoption of Superion has continued at a rapid and steady pace, driven by significant interest from both patients and treating physicians.”
Once implanted, Superion is intended to reduce pressure on the affected nerves and allow patients to return to a more active lifestyle. Following completion of a successful 391 patient randomized controlled trial, the Superion System received Premarket Approval (PMA) from the U.S. Food and Drug Administration (FDA), and starting January 2017 the system is described by a new American Medical Association (AMA) Current Procedural Terminology (CPT) Category I code.
“I’m also excited to see continued momentum with our current investors who have steadfastly supported the company to date, and look forward to working closely with our new investors to realize the potential for the Superion System, as we further invest in the commercial expansion of an important treatment option for physicians and patients,” Fender added.
To accommodate its accelerating growth, Vertiflex recently relocated its corporate headquarters from San Clemente, Calif., to a larger facility in Carlsbad, Calif. The new location includes expanded distribution capability, and a state-of-the-art physician education center, as part of the company’s commitment to supporting physicians by providing didactic as well as hands-on cadaver training with Superion.
Nick Shamie, M.D., Chief of Orthopedic Spine Surgery and Professor of Orthopedic Surgery and Neurosurgery at UCLA School of Medicine, stated, “The Superion System offers patients a minimally invasive solution to treat leg pain associated with spinal stenosis. The implant, placed through a small tube the size of a dime, does not deconstruct any of the anatomical elements and provides immediate relief. I incorporated this treatment into my practice after seeing the clinical data from the FDA IDE clinical trial. The safety, efficacy, and five-year durability that the data presented made it a procedure I can stand behind.”
  • Rear View Mirror Reflections

    Rear View Mirror Reflections

    Michael Barbella, Managing Editor||March 20, 2017
    AAOS past president discusses his tenure leading the organization.

  • The Shift to Outpatient Total Joint Replacements

    The Shift to Outpatient Total Joint Replacements

    Roger Massengale, General Manager, Acute Pain, Halyard Health||March 15, 2017
    As physicians look to shift patients to a same-day surgical option, technology addresses pain management.

  • Thrombosis: Examining New Preventative Measures

    Thrombosis: Examining New Preventative Measures

    Anthony Kjenstad, Founder and President, Athletic Recovery and Performance||March 9, 2017
    A new, wearable, wrist-watch sized device could offer patients a convenient alternative to current options.

  • Testing Your Patience

    Testing Your Patience

    Mark Crawford, Contributing Writer||March 22, 2017
    Changing FDA guidance and new technologies make device testing a challenging proposition for medtech OEMs.

  • Out of Ideas

    Out of Ideas

    Michael Barbella, Managing Editor||March 22, 2017
    Cost pressures, specialization, and customized solutions are currently driving orthopedic R&D.

  • Made of Sterner Stuff

    Made of Sterner Stuff

    Sam Brusco, Associate Editor||March 22, 2017
    Orthopedic materials are challenged to migrate away from metal while retaining metallic strength.